Skip to main content

Worse Overall Survival Seen for Adults With Leukemia With CNS Involvement

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 21, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Feb. 21, 2024 -- For adults with acute myeloid leukemia (AML), those with central nervous system (CNS) involvement have worse overall survival, according to a review published in the February issue of Leukemia Research.

Hannah Goulart, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a systematic review and meta-analysis to characterize survival outcomes in patients with AML with CNS involvement. Survival outcomes and response rates were examined from clinical studies of patients with AML stratified by CNS involvement. The meta-analysis included 12 studies.

The researchers found that overall survival was worse for patients with CNS involvement versus those without CNS involvement. In three studies examining complete remission, there was no significant difference observed for patients with versus without CNS involvement. Similarly, no significant difference was seen between CNS-positive versus CNS-negative patients in terms of disease-free survival or relapse-free survival outcomes based on five studies that included this outcome.

"We were able to identify through a meta-analysis that patients with AML and evidence of CNS involvement have inferior survival when compared to patients without CNS disease," the authors write.

Two authors disclosed ties to the pharmaceutical and biopharmaceutical industries.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Posttransplant Cyclophosphamide GVHD Prophylaxis Beneficial in Leukemia

MONDAY, June 24, 2024 -- For patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation, posttransplant cyclophosphamide (PTCy)...

New Neurocognitive/Functional Morbidity Explored in SARS-CoV-2, MIS-C

WEDNESDAY, June 12, 2024 -- Children with acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and multisystem inflammatory syndrome in children (MIS-C) with severe...

ASCO: Asciminib Has Superior Efficacy to TKIs for Newly Diagnosed Leukemia

WEDNESDAY, June 5, 2024 -- For patients with newly diagnosed chronic myeloid leukemia (CML), asciminib shows superior efficacy and a favorable safety profile compared with...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.